Murray Johnson, CRNA | |
825 Centennial Dr., Chadron, NE 69337-9400 | |
(308) 432-8176 | |
(308) 432-2737 |
Full Name | Murray Johnson |
---|---|
Gender | Male |
Speciality | Nurse Anesthetist, Certified Registered |
Location | 825 Centennial Dr., Chadron, Nebraska |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1124273354 | NPI | - | NPPES |
08596 | Other | NE | BCBS CRNA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
367500000X | Nurse Anesthetist, Certified Registered | 57237 (Nebraska) | Primary |
Mailing Address | Practice Location Address |
---|---|
Murray Johnson, CRNA 825 Centennial Dr., Chadron, NE 69337-9400 Ph: (308) 432-8176 | Murray Johnson, CRNA 825 Centennial Dr., Chadron, NE 69337-9400 Ph: (308) 432-8176 |
News Archive
A new approach to defining opioid-related auto fatalities provides insight into the nature and distribution of opioid-involved deaths in the state of Maryland, say the authors of a new study led by researchers at the Johns Hopkins Bloomberg School of Public Health.
In Alzheimer's disease proteins clump together to long fibrils causing the death of nerve cells. Small heat shock proteins can counteract this effect. Scientists, therefore, hope to deploy them as agents in the treatment of neurodegenerative diseases. Using the example of a small heat shock protein, researchers at the Technical University of Munich (TUM) and the Helmholtz Zentrum München have now uncovered how the protein interacts with other proteins.
Omeros Corporation today announced the launch of its initial public offering of 6.82 million shares of its common stock. Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system.
A multi-institutional team led by investigators from Memorial Sloan-Kettering Cancer Center has published a study that provides new insight into genetic changes that make some forms of glioblastoma, the most common type of primary brain cancer, more aggressive than others and explains why they may not respond to certain therapies. The research was led by senior author Eric C. Holland, MD, PhD,-an MSKCC surgeon, researcher and the Director of the Brain Tumor Center-and was published in the October 1 issue of the journal Genes & Development.
If a top London hospital gets the green light from its ethical committee, the world's first full face transplant may very well be carried out in Britain.
› Verified 5 days ago